Engimata is proud to announce that it was granted a US patent for its COVID-19 vaccine.
This patent is a step forward towards a thermostable COVID-19 vaccine which can be distributed at room temperature. It is also the second patent that Engimata received for its vaccine adjuvant platform.Patent:
Mosharraf, M., Sorayya, A., and Nayar, R., Immunogenic Composition Forming a SARS-COV-2 Vaccine, and a method for its manufacture, US Patent 11278617.Granted March 22, 2022.
For any inquiries, please contact us